Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination

Kurahashi, Yukiya; Furukawa, Koichi; Sutandhio, Silvia; Tjan, Lidya Handayani; Iwata, Sachiyo; Sano, Shigeru; Tohma, Yoshiki; Ohkita, Hiroyuki; Nakamura, Sachiko; Nishimura, Mitsuhiro; Arii, Jun; Kiriu, Tatsunori; Yamamoto, Masatsugu; Nagano, Tatsuya; Nishimura, Yoshihiro; Mori, Yasuko

doi:10.1101/2022.02.24.22271262

2022

DOI: 10.1101/2022.02.24.22271262

|View full text |Cite

Preprint

Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination

Yukiya Kurahashi

Koichi Furukawa

Silvia Sutandhio

et al.

Abstract: The SARS-CoV-2 variant Omicron is now under investigation. We evaluated cross-neutralizing activity against Omicron in COVID-19 convalescent patients who had received two doses of an mRNA vaccination. Surprisingly and interestingly, after the second vaccination, the subject neutralizing antibody titers including that against Omicron all became seropositive, and significant fold-increases were seen regardless of the subject disease severity. Our findings thus demonstrate that at least two doses of mRNA vaccina… Show more

Help me understand this report

View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Preprint2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Focosi

Franchini

Joyner

et al. 2021

Preprint

View full text Add to dashboard Cite

The novel SARS-CoV-2 Omicron variant of concern (VOCs), with its escape from unboosted vaccines and monoclonal antibodies, is demanding for a return to COVID19 convalescent plasma therapies. Lessons learnt from previous usage of CCP suggests focusing on outpatients and using high nAb-titer units in early disease stages. In this systematic analysis, we show that CCP from unvaccinated donors is not effective against Omicron, while CCP from vaccinees convalescents from previous VOCs or third-dose uninfected vaccinees is likely to remain effective against Omicron. countries. CCP remains the only antibody-based therapy that keeps up with the variants and provides an effective tool to combat the emergence of variants that defeat monoclonal antibodies. Consequently, there is a need for continue study of the variables that determine CCP efficacy.

show abstract

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Focosi

Franchini

Joyner

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Novel monoclonal antibodies showing broad neutralizing activity for SARS-CoV-2 variants including Omicrons BA.5 and BA.2.75

Ishimaru

Nishimura

Tjan

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

We identified novel neutralizing monoclonal antibodies against SARS-CoV-2 variants (including Omicron) from individuals received two doses of mRNA vaccination after they had been infected with wildtype. We named them MO1, MO2 and MO3. MO1 shows high neutralizing activity against authentic variants: D614G, Delta, BA.1, BA.1.1, BA.2, and BA.2.75 and BA.5. Our findings confirm that the wildtype-derived vaccination can induce neutralizing antibodies that recognize the epitopes conserved among the SARS-CoV-2 variants (including BA.5 and BA.2.75). The monoclonal antibodies obtained herein could serve as novel prophylaxis and therapeutics against not only current SARS-CoV-2 viruses but also future variants that may arise.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination

Cited by 2 publications

References 15 publications

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Novel monoclonal antibodies showing broad neutralizing activity for SARS-CoV-2 variants including Omicrons BA.5 and BA.2.75

Contact Info

Product

Resources

About